Millions suffering from depression, PTSD, or addiction often endure slow, short-lived relief from current treatments, especially when symptoms resist existing treatment options.
However, new research is exploring alternative treatments for these conditions. In a recent interview with Genomic Press, Swiss psychiatrist Gregor Hasler demonstrated how psychedelics can rapidly reorganize brain function, with the potential to deliver stronger, longer-lasting benefits than conventional approaches.
Integrating both traditional and innovative approaches, Hasler serves as Chair of Psychiatry at the University of Fribourg and Director of its Molecular Psychiatry Laboratory. He regards psychedelics such as LSD, psilocybin, and MDMA as more than just symptom suppressors, describing them as triggers for neuroplasticity, the process by which the brain reorganizes its connections, potentially leading to longer-lasting recovery.
Hasler’s research builds on Switzerland’s long tradition of mental health innovation, a history that ranges from the creation of early antidepressants and benzodiazepines to Albert Hofmann’s discovery of LSD. Initially trained in psychoanalysis, he later pursued neuroscience research at the U.S. National Institute of Mental Health, where his mentors encouraged him to investigate substances with rapid and robust effects.
This broad foundation enhances Hasler’s expertise in both psychology and molecular psychiatry, helping him connect brain chemistry with clinical outcomes. His studies of glutamate and GABA neurotransmitter systems have changed how scientists view mood disorders. He also helped identify mGluR5 as a potential biomarker linked to neuroplasticity and nicotine dependence, which helped bridge laboratory findings with patient care.
The Science of Rapid Rewiring
Traditional antidepressants usually take several weeks before any noticeable change occurs. By comparison, treatments that involve psychedelics often act far more quickly. In some studies, participants reported noticeable changes after only a few carefully guided sessions. In certain cases, these improvements lasted for months and sometimes even years. Hasler’s research suggests the reason lies in neuroplasticity; psychedelics seem to help the brain reorganize its circuits, making it easier to break free from the rigid patterns that fuel depression, PTSD, and addiction.
Conventional treatments often manage symptoms. Psychedelic therapy can change the very architecture of how the brain processes experience. Hasler’s findings point to psychedelics as a possible way forward for conditions long seen as untreatable, including trauma-related disorders and even post-stroke rehabilitation.
Balancing Innovation with Caution
Despite these advances, interest in psychedelic therapy comes with practical challenges. Hasler separates careful clinical research from wider efforts to legalize these substances. As President of the Swiss Society for Drug Safety in Psychiatry and a member of the American College of Neuropsychopharmacology, he continues to support systems that focus on maximizing benefits while reducing risks.
Hasler emphasized the importance of safety, training, and ethics to guide the integration of psychedelic therapy into public healthcare. Through their research, his lab is creating protocols and guidelines to ensure both patient safety and continued innovation.
A Personal Mission
This research is also personal for Hasler, who credits his father, a mathematician and economist, with shaping his career by highlighting that depression is both a human and economic burden. That influence led him toward psychiatry, motivated by the conviction that improving mental health care is among the most meaningful contributions science can make.
This influence continues to shape Hasler’s approach. He merges neuroimaging and clinical research to analyze how psychedelics affect consciousness and brain activity. The scope of his research extends beyond simply easing symptoms; he hopes to discover treatments that spark genuine growth and lasting recovery with the potential to redefine the field of psychiatry.
The Psychedelic Renaissance
Research teams across the world are building on Hasler’s findings and pushing psychiatry to a pivotal moment. Open-access platforms are helping discoveries spread faster than ever, while changes in policies in Australia and certain states in the U.S. are accelerating their adoption in clinics. The question that remains is how much of an impact the application of psychedelics could have on the practice of psychiatry.
Hasler sees the future as a matter of striking the right balance. He remains committed to supporting approaches rooted in solid scientific evidence that maximize positive outcomes and keep risks in check. As interest in psychedelics rises during what he calls a defining period in his career, Hasler recognizes his unique opportunity to help guide changes that may redefine mental health care for years to come.
Austin Burgess is a writer and researcher with a background in sales, marketing, and data analytics. He holds a Master of Business Administration and a Bachelor of Science in Business Administration, along with a certification in Data Analytics. His work combines analytical training with a focus on emerging science, aerospace, and astronomical research.